Nav1.2 x SIRT1 x hERG x nAChRα9&α10 x PI4K - 药物、适应症、专利

A Multicentre Randomized Controlled Study of Anti-angiogenic Targeted Drugs Combined With Ginsenoside Rg3 to Improve the Efficacy of Transcatheter Arterial Chemoembolization (TACE) in the Treatment of Unresectable Hepatocellular Carcinoma

The aim of this study is to compare the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with the anti-angiogenic targeted drugs and ginsenoside Rg3 versus TACE alone in patients with unresectable Barcelona Clinic Liver Cancer (BCLC) stage B/C hepatocellular carcinoma (HCC), who has normal liver function and no extrahepatic metastasis.

开始日期2020-12-01

申办/合作机构

上海东方肝胆医院

100 项与 Nav1.2 x SIRT1 x hERG x nAChRα9&α10 x PI4K 相关的临床结果

登录后查看更多信息

100 项与 Nav1.2 x SIRT1 x hERG x nAChRα9&α10 x PI4K 相关的转化医学

登录后查看更多信息

0 项与 Nav1.2 x SIRT1 x hERG x nAChRα9&α10 x PI4K 相关的专利（医药）

登录后查看更多信息

分析

对领域进行一次全面的分析。

登录

或

查看完整样例数据